Anju Ghangurde
Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express. She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Advertisement
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Anju Ghangurde
Can Lilly's Olumiant Prickle Xeljanz In India?
Lilly’s Olumiant has hit the Indian market, upping the level of competition in a rheumatoid arthritis sector that already includes the fellow JAK inhibitor Xeljanz from Pfizer and at least half a dozen biosimilar versions of Humira, among other products. But could pricing cloud Olumiant’s uptake?
India Keeps Eye On SGLT2 Inhibitors Amid Safety Signals
After recent safety warnings from both US FDA and Health Canada, India steps ups surveillance, but Janssen and AstraZeneca tell Pink Sheet that data indicate no major safety concerns, at least so far.
Cipla Rejigs Deck As Global Head Of Operations Moves On
Cipla’s global head (operations) Raju Subramanyam is leaving the firm to pursue his own ambitions. The exit has resulted in an interesting portfolio rejig at the Mumbai-based firm, known for its generally clear manufacturing compliance record.
More Manufacturing Rationalization On The Cards At Dr Reddy’s?
Dr Reddy’s quest to emerge as an “internationally cost-competitive and more nimble organization” is expected to entail further rationalization of the firm’s manufacturing network. The company may put on the block a formulations site in India, if the buzz on deal street is to be believed.
Could Contentious IPR Trade Terms Bloat Healthcare Costs, Sink Pharma’s Image?
Intellectual property rights terms in various trade agreements could have serious ramifications not just on healthcare costs but also on the legitimate trade of generic drugs between developing nations, say some experts. Pharma’s image may be at stake too.
Sun Wards Off Volini Infringers, Makes It Count Too
Sun Pharma has blocked a group of firms attempting to ride on the trademark of its popular pain relief brand Volini – among the key products at the core of the Indian firm’s OTC business.
Advertisement